Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9

Molecular Cancer Research

Volumn 11, Issue 12, 2013, Pages 1487-1496

  Zhang, Hui ^a   Chen, Yiqian ^a   Keane, Fiona M ^a   Gorrell, Mark D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 8 INHIBITOR; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE 9 INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; UNCLASSIFIED DRUG;

CELL FUNCTION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENETIC ANALYSIS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW;

ANIMALS; CATALYTIC DOMAIN; DIPEPTIDASES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; INFLAMMATION; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; SUBSTRATE SPECIFICITY;

EID: 84887494249     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0272     Document Type: Review

References (80)

1. Turk B, Turk D, Turk V. Protease signalling: the cutting edge. EMBO J 2012;31:1630-43.
2. Abbott CA, Yu DMT, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000;267:6140-50.
3. Olsen C, Wagtmann N. Identification and characterization of human Dpp9, a novel homologue of dipeptidyl peptidase IV. Gene 2002;299: 185-93.
4. Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 2005;280:19441-4.
5. De Meester I. Dipeptidyl peptidase 9. In:Rawlings NL, Salvesen G, editors. Handbook of proteolytic enzymes, 3rd ed. San Diego: Elsevier; 2013. p. 3384-9.
6. Abbott C, Gorrell M. Dipeptidyl peptidase 8. In:Rawlings NL, Salvesen G, editors. Handbook of proteolytic enzymes. 3rd ed. San Diego: Elsevier; 2013. p. 3379-84.
7. Gorrell MD, Park JE. Fibroblast activation protein a. In: Rawlings NL, Salvesen G, editors. Handbook of proteolytic enzymes. 3rd ed. San Diego: Elsevier; 2013. p. 3395-401.
8. Deacon CF, Danielson P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001;50:1588-97.
9. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.
10. Mersmann M, Schmidt A, Rippmann JF, Wuest T, Brocks B, Rettig WJ, et al. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. Int J Cancer 2001;92:240-8.
11. Wuest T, Moosmayer D, Pfizenmaier K. Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J Biotechnol 2001;92:159-68.
12. Gorrell MD, Song S, Wang XM. Novel metabolic disease therapy. International patent application WO 2010/083570; 2010.
13. Yu DMT, Yao T-W, Chowdhury S, Nadvi NA, Osborne B, Church WB, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010;277:1126-44.
14. Keane FM, Chowdhury S, Yao T-W, Nadvi NA, Gall MG, Chen Y, et al. Targeting dipeptidyl peptidase-4 (DPP-4) and fibroblast activation protein (FAP) for diabetes and cancer therapy. In:Dunn B, editor Proteinases as drug targets. RSC drug discovery series, vol. 18. Cambridge, UK: Royal Society of Chemistry; 2012. p. 119-45.
15. Liu R, Li H, Liu L, Yu J, Ren X. Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther 2012;13:123-9.
16. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7.
17. Reinhold D, Goihl A, Wrenger S, Reinhold A, Kühlmann UC, Faust J, et al. Role of dipeptidyl peptidase IV (DPIV)-like enzymes in T lymphocyte activation: investigations in DPIV/CD26 knockout mice. Clin Chem Lab Med 2009;47:268-74.
18. Wu JJ, Tang HK, Yeh TK, Chen CM, Shy HS, Chu YR, et al. Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol 2009;78:203-10.
19. Van Goethem S, Matheeussen V, Joossens J, Lambeir AM, Chen X, De Meester I, et al. Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? J Med Chem 2011;54:5737-46.
20. Wu W, Liu Y, Milo LJJr, Shu Y, Zhao P, Li Y, et al. 4-Substituted boroproline dipeptides: synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities. Bioorg Med Chem Lett 2012;22:5536-40.
21. Zhu H, Zhou ZM, Lu L, Xu M, Wang H, Li JM, et al. Expression of a novel dipeptidyl peptidase 8 (DPP8) transcript variant, DPP8-v3, in human testis. Asian J Androl 2005;7:245-55.
22. Bjelke JR, Christensen J, Nielsen PF, Branner S, Kanstrup AB, Wagtmann N, et al. Dipeptidyl peptidase 8 and 9 specificity and molecular characterization compared to dipeptidyl peptidase IV. Biochem J 2006;396:391-9.
23. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochem. Biophys. Acta 2004;1679:18-28.
24. Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992;149:481-6.
25. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein alpha, amember of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A 1994;91:5657-61.
26. Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W, et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett 2006;580:1581-6.
27. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013;45:613-20.
28. Wang ZJ, Churchman M, Campbell IG, Xu WH, Yan ZY, McCluggage WG, et al. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer 1999;80: 70-2.
29. Bruford EA, Riise R, Teague PW, Porter K, Thomson KL, Moore AT, et al. Linkage mapping in 29 Bardet-Biedl syndrome families confirms loci in chromosomal regions 11q13, 15q22.3-q23, and 16q21. Genomics 1997;41:93-9.
30. Qiu XS, Tang NLS, Yeung HY, Qiu Y, Cheng JCY. Association study between adolescent idiopathic scoliosis and the DPP9 gene which is located in the candidate region identified by linkage analysis. Postgrad Med J 2008;84:498-501.
31. Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organisation, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994;40:331-8.
32. Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 2007;66:160-71.
33. Park J, Knott HM, Nadvi NA, Collyer CA, Wang XM, Church WB, et al. Reversible inactivation of human dipeptidyl peptidases 8 and 9 by oxidation. The Open Enz Inhib J 2008;1:52-61.
34. Lee HJ, Chen YS, Chou CY, Chien CH, Lin CH, Chang GG, et al. Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8. J Biol Chem 2006;281:38653-62.
35. Tang HK, Chen KC, Liou GG, Cheng SC, ChienCH, Tang HY, et al. Role of a propeller loop in the quaternary structure and enzymatic activity of prolyl dipeptidases DPP-IV and DPP9. FEBS Lett 2011;585:3409-14.
36. Ajami K, Abbott CA, Obradovic M, Gysbers V, Kähne T, McCaughan GW, et al. Structural requirements for catalysis, expression and dimerisation in the CD26/DPIV gene family. Biochemistry 2003;42:694-701.
37. Abbott CA, McCaughan GW, Gorrell MD. Two highly conserved glutamic acid residues in the predicted b propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett 1999;458: 278-84.
38. Wang XM, Yu DMT, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology 2005;42:935-45.
39. Pitman MR, Menz RI, Abbott CA. Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DPP8). Biol Chem 2010;391:959-72.
40. Tang HK, Tang HY, Hsu SC, Chu YR, Chien CH, Shu CH, et al. Biochemical properties and expression profile of human prolyl dipeptidase DPP9. Arch Biochem Biophys 2009;485:120-7.
41. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325:834-40.
42. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010;327: 1000-4.
43. Pilla E, Möller U, Sauer G, Mattiroli F, Melchior F, Geiss-Friedlander R. A novel SUMO1-specific interacting motif in dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. J Biol Chem 2012;287:44320-9.
44. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007;8:947-56.
45. Dubois V, Lambeir A-M, Vandamme S, Matheeussen V, Guisez Y, Scharpé S, et al. Dipeptidyl peptidase 9 (DPP9) from bovine testes: Identification and characterization as the short form by mass spectrometry. Biochem. Biophys. Acta 2010;1804:781-8.
46. Geiss-Friedlander R, Parmentier N, Moeller U, Urlaub H, Van den Eynde BJ, Melchior F. The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem 2009;284: 27211-9.
47. Wilson CH, Indarto D, Doucet A, Pogson LD, Pitman MR, Menz RI, et al. Identifying natural substrates for dipeptidyl peptidase 8 (DP8) and DP9 using terminal amine isotopic labelling of substrates, TAILS, reveals in vivo roles in cellular homeostasis and energy metabolism. J Biol Chem 2013;288:13936-49.
48. Fukasawa KM, Fukasawa K, Hiraoka BY, Harada M. Characterization of a soluble form of dipeptidyl peptidase IV from pig liver. Experientia 1983;39:1005-7.
49. Ajami K, Pitman MR, Wilson CH, Park J, Menz RI, Starr AE, et al. Stromal cell-derived factors 1a and 1b, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 2008;582:819-25.
50. Frerker N, Wagner L, Wolf R, Heiser U, Hoffmann T, Rahfeld J-U, et al. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides 2007;28:257-68.
51. Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, et al. Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. J Biol Chem 2011;286:27494-505.
52. Lankas G, Leiting B, Roy R, Eiermann G, Beconi M, Biftu T, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94.
53. Chen SJ, Jiaang WT. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein. Curr Top Med Chem 2011;11:1447-63.
54. Van der Veken P, De Meester I, Dubois V, Soroka A, Van Goethem S, Maes MB, et al. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. Bioorg Med Chem Lett 2008;18:4154-8.
55. Van Goethem S, Van der Veken P, Dubois V, Soroka A, Lambeir AM, Chen X, et al. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. Bioorg Med Chem Lett 2008;18:4159-62.
56. Jiaang WT, Chen YS, Hsu T, Wu SH, Chien CH, Chang CN, et al. Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett 2005;15:687-91.
57. Van der Veken P, Soroka A, Brandt I, Chen YS, Maes MB, Lambeir AM, et al. Irreversible inhibition of dipeptidyl peptidase 8 by dipeptidederived diaryl phosphonates. J Med Chem 2007;50:5568-70.
58. Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J 2003;373:179-89.
59. Yu DMT, Ajami K, Gall MG, Park J, Lee CS, Evans KA, et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 2009;57:1025-40.
60. Yao T-W, Kim W-S, Yu DM, Sharbeen G, McCaughan GW, Choi K-Y, et al. A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res 2011;9:948-59.
61. Chowdhury S, Chen Y, Yao T-W, Ajami K, Wang XM, Popov Y, et al. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. World J Gastroenterol 2013;19:2883-93.
62. Maes M-B, Dubois V, Brandt I, Lambeir A-M, Van der Veken P, Augustyns K, et al. Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol 2007;81:1252-7.
63. Dubois V, Ginneken CV, De Cock H, Lambeir A-M, Van der Veken P, Augustyns K, et al. Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem 2009;57:531-41.
64. Harstad EB, Rosenblum JS, Gorrell MD, Achanzar WE, Minimo L,Wu J, et al. DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues. Regul Pept 2013;186:26-35.
65. Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van Der Veken P, Augustyns K, et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011;392:189-98.
66. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 2003;228:882-90.
67. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13:7-18.
68. Yu DMT, Wang XM, McCaughan GW, Gorrell MD. Extra-enzymatic functions of the dipeptidyl peptidase (DP) IV related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J 2006;273: 2447-61.
69. Matheeussen V, Waumans Y, Martinet W, Van Goethem S, Van der Veken P, Scharpe S, et al. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 2013;108:350.
70. Wilson C, Abbott C. Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines. Int J Oncol 2012;41: 919-32.
71. Stremenova J, Mares V, Lisa V, Hilser M, Krepela E, Vanickova Z, et al. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas. Int J Oncol 2010;36:351-8.
72. Sulda ML, Abbott CA, Macardle PJ, Hall RK, Kuss BJ. Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia. Cancer Biol Ther 2010;10: 180-9.
73. Spagnuolo PA, Hurren R, Gronda M, Maclean N, Datti A, Basheer A, et al. Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity. Leukemia 2013; 27:1236-44.
74. Walsh MP, Duncan B, Larabee S, Krauss A, Davis JP, Cui Y, et al. Val-BoroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors. PLoS ONE 2013;8:e58860.
75. Bank U, Heimburg A, Wohlfarth A, Koch G, Nordhoff K, Julius H, et al. Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects. Biol Chem 2011;392:169-87.
76. Kruschinski C, Skripuletz T, Bedoui S, Tschernig T, Pabst R, Nassenstein C, et al. CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol 2005;139:17-24.
77. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008;29:295-301.
78. Schade J, Stephan M, Schmiedl A, Wagner L, Niestroj AJ, Demuth HU, et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 2008;56:147-55.
79. Yazbeck R, Sulda ML, Howarth GS, Bleich A, Raber K, von Horsten S, et al. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis 2010;16:1340-51.
80. Röhnert P, Schmidt W,Emmerlich P, Goihl A, Wrenger S, Bank U, et al. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflam 2012;9:44.